About

EASD 2023

59th Annual EASD 2023 - European Association for the study of Diabetes 2nd-6th Oct

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease

FDA

Brenzavvy (bexagliflozin) approved by the FDA in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

Publication thumbnail: Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): a Multicentre, Randomised, Active-controlled,  Phase 2b, Clinical Trial

Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): a Multicentre, Randomised, Active-controlled, Phase 2b, Clinical Trial

Steering Committee